Arylpiperazinylbutyl-dihydroindoles and related compounds
CA 2006356 C · Owner: Stenberg, John Willie · Inventors: Stenberg, John Willie; Perregaard, Jens
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to novel piperazinylbutyldihydroindoles, piperazinylbutylindazoles the corresponding, 2,3-dihydro derivatives and 2-indolones, having the, following formula wherein the various symbols have the meanings set forth herein, which have been found to have central serotonin activity with preference for the serotonin 5-HT1A receptor. Compared to the anxiolytic drug buspirone and other clinically investigated, compounds such as ipsapirone and gepirone most of the present compounds have, lower efficacy at the 5-HT1A receptor which implies less side effects related to, activation of the receptors. The invention also includes acid addition salts and pharmaceutical …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 21, 1989 and granted September 14, 1999. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 21, 2009.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 21, 2011.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.